Recognising the value of collaboration
In addition to a well-established pipeline of wholly-owned programmes, Immunocore's transformational science has led to multi-target discovery partnerships with Genentech, Eli Lilly, GlaxoSmithKline and AstraZeneca to develop new cancer therapies using the ImmTAC® technology platform.
Both the Genentech and Eli Lilly partnerships include a co-development/co-promotion arrangement in addition to ImmTAC® molecule co-discovery.
Outside of oncology, the Bill and Melinda Gates Foundation is supporting the expansion of Immunocore's technology platform to develop ImmTAV®/ImmTAB® molecules for the treatment of infectious diseases, including HIV. In addition, the Juvenile Diabetes Research Foundation is partnering with Immunocore on our type 1 diabetes program.